Carbiotix selected as most promising European biotech startup
Jul 15, 2019
Carbiotix, an award winning pre-clinical stage therapeutics company leveraging low-cost gut health
testing and microbiome modulators to unlock the potential of the gut microbiome to address a range
of chronic and metabolic diseases, has been selected as one of the top 15 most promising biotech
startups in Europe by Startup City.
"Being selected as one of the 15 most promising startups in Europe is an honor and I believe reflects
our overall competitive position and potential to develop effective microbiome therapeutics across
multiple disease areas. We are entering an exciting phase of company’s development, where our work
over the past four years with our prebiotic fiber AXOS, low cost gut health testing platform and
early therapeutics development, will be used as a base to accelerate the clinical introduction of
two therapeutic products and hopefully many more over the coming years," says Carbiotix CEO, Kristofer Cook.
Startup City is a US based independent platform for decision makers in various industries, providing
an inside look at various solutions from the burgeoning startup ecosystem. Startup City operates the
Startup City Magazine and website that aim to bring together investors, accelerators, CIOs, and CEOs
with startups under one roof to shed light on audacious solutions. This is the first year that Startup
City has selected and published a list of the top 15 promising biotech startups based exclusively in Europe.